_levels_detect_early_preeclampsia1746032699.png)
Can glycosylated fibronectin (GlyFn) help diagnose preeclampsia in early pregnancy?
Although there is no definitive treatment for preeclampsia, early screening and detection can allow patients to ensure proper management throughout the remainder of the pregnancy.
Currently, preeclampsia is diagnosed through clinical assessment, which involves a physical examination, laboratory testing, and imaging such as ultrasound. This process of prenatal testing involves measuring biomarkers – biological substances that can signal the presence of a medical condition. For instance, high cholesterol can serve as a biomarker for heart disease risk.
In this study, scientists looked at a potential biomarker for preeclampsia: maternal serum glycosylated fibronectin (GlyFn) levels. GlyFn is a protein found in maternal blood that is secreted by the liver and other body tissues. Changes in GlyFn levels may reflect impaired vascular function, making it a promising early indicator for preeclampsia.
Researchers collected and analyzed results from 11 global studies on GlyFn levels, six in Europe and four in Asia. They looked at whether GlyFn levels were different in pregnant women with preeclampsia compared to those without the condition. From these findings, they could evaluate how accurate GlyFn tests were at identifying preeclampsia in pregnant individuals.
As a result, the researchers found that GlyFn levels were consistently higher in women with preeclampsia. In six of the studies that assessed diagnostic accuracy, the GlyFn test correctly identified 81% of preeclampsia cases and reported high statistical test accuracy. These results were supported across a majority of the studies, with strong measures of sensitivity and specificity reinforcing the link between elevated GlyFn levels and preeclampsia.
The researchers concluded that maternal serum GlyFn could be a promising new tool for detecting preeclampsia early on in pregnancy. We can expect to see GlyFn used as a potential biomarker for the diagnosis of preeclampsia, providing a more accurate, fast, and cost-effective approach for improving both maternal and child health.
Take Home: Maternal serum glycosylated fibronectin (GlyFn) is emerging as a potential
effective first-trimester biomarker for assessing risk for preeclampsia. More research will be ongoing to test its ability to be used as a tool.
Citation: Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis
Link: https://doi.org/10.1186/s12884-025-07243-6
ABOUT RESEARCH ROUNDUP
Each quarter, our team of science writers reviews the most current research studies related to hypertensive disorders of pregnancy and summarizes those studies of greatest interest and potential impact to our community, including research studies related to risk assessment, diagnosis, prevention, and treatment. Special thanks to our volunteer research team, including Dr. Sig-Linda Jacobson, Dr. Jennifer Mitchell, Dr. Julie Reynolds, and Amanda Yang who make Research Roundup possible, and to our Patient Advisory Council, who reviews these materials from the patient perspective.
Related Articles
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
Hypertensive disorders of pregnancy significantly increase your risk of developing long-term heart problems. A careful review of blood pressure elevations during and after pregnancy may assist in iden...
Hypertensive disorders of pregnancy (HDP) can affect different groups of women in different ways, and even though we know this happening, we don't fully understand why. There are many factors, like bi...
There is growing evidence that studies examining pregnancy and its complications need to start early within the pregnancy to fully understand the nature of preeclampsia. Key gestational milestones, wh...
It is known that chronic hypertension and high BMI (body mass index) are risk factors for hypertensive disorders of pregnancy (HDP). Studies documenting this risk have usually assessed blood pre...
Several biomarker tests are under development to predict or diagnose preeclampsia. While none of these tests are yet widely accepted in U.S. clinical practice, two FDA-approved tests are available in...